Zealand Pharma CEO undeterred by lower than expected Zegalogue sales
Emmanuel Dulac, CEO of Zealand Pharma, is not disappointed that the biotech company's blood sugar pen Zegalogue has generated worse sales figures than expected for 2021. The CEO highlights that the bar was set high.
Zegalogue, an emergency auto-injector pen and Zealand Pharma's first independently launched product, entered the US market in June.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma enters US partnership over pump system
For subscribers
Zealand Pharma sends obesity candidate to clinic
For subscribers
.jpg&w=384&q=75)
